Clinical trials: Oncologic Diseases
Pediatric Cancer, Febrile Neutropenia
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Chemotherapy-induced Neutropenia, Oncology
- Trial name
- NCT04134429
- Testing
- Everion
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bladder Cancer
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in…
- Trial name
- NCT00234494
- Testing
- Cisplatin, Gemcitabine, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Christopher Sweeney, MBBS
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Small Cell Lung Cancer
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed.
- Trial name
- NCT00613626
- Testing
- Cisplatin, Etoposide, ZD6474
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Hoosier Cancer Research Network
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Smoking Cessation
Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Evaluate a multi-faceted training program to improve short-term smoking cessation rates (<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed…
- Trial name
- OaSiS (NCT03291587)
- Testing
- Personnel Training and Coaching Calls
- Where
- 49 sites in United States
- Volunteers
- 1,094 people
- Sponsor
- Wake Forest University Health Sciences
Cancer, Tumor, Solid
Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)
The purpose of this study is to assess the performance and safety of Biology-Guided Radiotherapy (BgRT) using the RefleXion Medical Radiotherapy System (RMRS) via optimizing F18-Fluorodeoxyglucose (FDG) dosing, assessing the…
- Conditions
- Cancer, Tumor, Solid, Cancer, Lung, Cancer, Bone
- Trial name
- BIOGUIDE-X (NCT04788147)
- Testing
- RMRS IDE Device
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- RefleXion Medical
Hepatocellular Carcinoma
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo…
- Trial name
- NCT05359861
- Testing
- Casdozokitug, Atezolizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Coherus Oncology, Inc.
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
AZD9291 First Time In Patients Ascending Dose Study
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment.
- Trial name
- AURA (NCT01802632)
- Testing
- AZD9291
- Where
- 45 sites in United States, Australia and 8 more
- Volunteers
- 603 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.
- Trial name
- NCT01186458
- Testing
- Fludarabine, Velcade, Rituximab
- Where
- 11 sites in United States
- Volunteers
- 4 people
- Sponsor
- Hoosier Cancer Research Network
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Non-small Cell Lung Cancer, Lung Cancer
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
- Trial name
- NCT02469701
- Testing
- nivolumab and ablation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- howard safran
Non-Small Cell Lung Cancer
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
Pemetrexed is approved for second line therapy in metastatic NSCLC. Given the single-agent activity of pemetrexed and the tolerability of pemetrexed in combination with radiation, this study will evaluate survival rates and…
- Trial name
- NCT00732303
- Testing
- Pemetrexed, Radiation Therapy
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoosier Cancer Research Network
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
The purpose of this study was to evaluate the efficacy and effect of palifermin on the incidence of oral mucositis in subjects with multiple myeloma receiving Melphalan followed by autologous peripheral blood stem cell…
- Trial name
- NCT00434161
- Testing
- Palifermin before only, Palifermin before and after
- Where
- Germany
- Volunteers
- 281 people
- Sponsor
- Swedish Orphan Biovitrum
Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
- Trial name
- NCT04106492
- Testing
- SQ3370
- Where
- 10 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Shasqi, Inc.
Neuroblastoma
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed…
- Trial name
- NCT01313936
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6…
- Trial name
- NCT00526799
- Testing
- Sorafenib, Topotecan
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daniela Matei, MD